GlassScriptPhysician profile
Nasar Munir Katariwala
NPI 1356311310
$14,758.39
in general payments reported to CMS, 2019-2025
60 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,036 · 2020: $1,538 · 2021: $1,721 · 2022: $2,526 · 2023: $1,815 · 2024: $1,305 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,937.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,198.79 | 2019-2025 | |
| Abbvie INC. | $759.32 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $540.02 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sk Life Science, INC. | $536.28 | 2020-2025 | |
| Emd Serono, INC. | $515.05 | 2019-2025 | Mavenclad |
| Ucb, INC. | $494.08 | 2019-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Lilly USA, LLC | $476.37 | 2020-2024 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $459.34 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Janssen Pharmaceuticals, INC | $416.17 | 2019-2023 | Ponvory |
| Sunovion Pharmaceuticals INC. | $357.48 | 2019-2022 | |
| Genzyme Corporation | $356.75 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $351.00 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $327.74 | 2020-2025 | Vyepti |
| Argenx US, INC. | $261.53 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals INC. | $256.88 | 2022-2023 | Trudhesa |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasar Katariwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.